Results 231 to 240 of about 457,686 (270)

Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia

American Journal of Hematology, EarlyView.
ABSTRACT Preclinical studies showed a synergistic antileukemia activity with combination of selective XPO1 inhibitor selinexor (SEL) and venetoclax (VEN), with potential to overcome VEN resistance by reducing the anti‐apoptotic protein MCL1. In an investigator‐sponsored, open‐label, phase Ib study (NCT03955783), adult patients with relapsed or ...
Somedeb Ball, Farrukh T. Awan, Ben K. Tomlinson, Tess Stopczynski, Melissa A. Fischer, Zhiguo Zhao, Kateryna Fedorov, Ashwin Kishtagari, Sanjay R. Mohan, Gregory D. Ayers, Michael T. Byrne, Michael R. Savona   +11 more
wiley   +1 more source

Changes in the prevalence of adolescent tobacco use and its associated factors in Indonesia: analysis of repeated cross-sectional survey 2009-2019. [PDF]

BMJ Open
Suryadarma AY, Saputro SA, Isnuwardana R, Destiwi M, Bassey PE, Martini S, Sebayang SK.   +6 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry

American Journal of Hematology, EarlyView.
ABSTRACT Ravulizumab, a second‐generation complement component 5 inhibitor (C5i) derived from eculizumab, with improved pharmacokinetics, is the current standard‐of‐care treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), where available.
Alexander Röth, Christopher J. Patriquin, Jeff Szer, Louis Terriou, Ami S. Patel, Jesse Metzger, Philippe Gustovic, Jun‐ichi Nishimura, Robert A. Brodsky   +8 more
wiley   +1 more source

Preface to "Minimally Invasive Treatments for Urethral Stenosis". [PDF]

Transl Androl Urol
Wiegand L.
europepmc   +1 more source

From methods to policy: a critical appraisal of the 2024 ECDC guidance on enhanced influenza vaccines. [PDF]

Front Public Health
Ortiz de Lejarazu R, Ocaña D, Arrazola P, Orrico-Sánchez A, Redondo E, Sanz-Muñoz I, Tolosa N, Trilla A.   +7 more
europepmc   +1 more source

A comprehensive analysis of dry eye disease clinical trials (2000-2024): research trends and gaps. [PDF]

Front Pharmacol
Jiang X, Xu B, Xu R, Wu N, Tian S, Peng H, Zhao YE.   +6 more
europepmc   +1 more source

Abundant A-to-I RNA editing in spermatocytes may suppress transposons to compensate for piRNA downregulation in male germlines. [PDF]

RNA Biol
Duan Y, Xie Q, Ma L, Cao Q.
europepmc   +1 more source

Author's comments on RECAP-MEP trial. [PDF]

Surg Neurol Int
Suresh S, Hrishi AP, Thiruvathra J, Divakar G.   +3 more
europepmc   +1 more source

Introducing AI & Innovation

AI &Innovation, EarlyView.
Mirko Farina, Xiao Yu, Rongrong Ji, Chen Jin, Vincent Blok, Paolo Ciancarini, Ngcaweni Busani, Witold Pedrycz   +7 more
wiley   +1 more source